
Student Research
Papers
GENE 226:
Longevity
Venture Capital
Instructors for this course:
Michael Snyder, PhD
Stanford W. Ascherman, MD, FACS, Professor in Genetics
Ronjon Nag, PhD
Adjunct Professor in Genetics, Stanford School of Medicine
Director, R42 Longevity Fund
Anastasiya Giarletta
Principal, R42 Fund
Gene 226 Teaching Assistant
Longevity covers therapeutics, robotics, and fintech. Yet as an emerging industry how do these get financed when they are so risky?
How should venture firms evaluate longevity companies and how should founders attract investors and employees?
- This course will look at these questions specifically as applied to longevity, uniquely from the investor, scientist, and the founder viewpoint.
- After providing a foundation to the field we will interact with guest lectures from investors, scientists and company founders who can explain their respective perspectives.
- The course will cover finance and science aspects of longevity though no pre-requisites are expected.
Infectious Disease and COVID-19 Wearables Study
Can wearables help detect Infectious Disease or COVID-19 before symptoms emerge? Learn More >